Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"EA Pharma","sponsor":"Eisai","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"All-case Surveillance Condition for Approval of \u201cActonel\u00ae 17.5 mg tablets\u201d for Treatment of Paget\u2019s Disease of Bone Cleared in Japan","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Risedronate Sodium Hydrate

    Menu

    Risedronate Sodium Hydrate

    APIs // Active Pharmaceutical Ingredients

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    DOSSIERs // Finished Dosage Forms

    DRUG PRODUCT COMPOSITION

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS

    ANALYTICAL SOLUTION(s)

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              EA Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag France
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              All-case Surveillance Condition for Approval of “Actonel® 17.5 mg tablets” for Treatment of Paget’s Disease of Bone Cleared in Japan

              Details:

              Actonel (risedronate sodium hydrate) tablet act as inhibits osteoclasts, which is indicated for the treatment of Paget’s disease and treatment and prevention of postmenopausal osteoporosis.

              Lead Product(s): Risedronate Sodium

              Therapeutic Area: Rare Diseases and Disorders Product Name: Actonel

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Eisai

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable March 19, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Risedronate Sodium
              Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.
              Close
              4
              Post Enquiry
              POST ENQUIRY